DOC1021
Phase 2Biologic
DOC1021 is one of 52 biologic programs targeting Adult Glioblastoma. It is currently in Phase 2.
4
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 3
ABI-007
Bristol-Myers SquibbPhase 3
Rhuph20
Bristol-Myers SquibbPhase 3
Interferon-Gamma
SSPP Pharmaclon Ltd.
Phase 3
Tumor Necrosis Factor
NNational Cancer Institute (NCI)
Phase 3
IBI308
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
High-Dose Recombinant Interferon A-2b
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
DOC1021
DDiakonos Oncology Corporation
Phase 2
Intron a
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DOC1021. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- DDiakonos Oncology Corporation